Volta Labs and Watchmaker Genomics Partner to Simplify and Optimize NGS Library Prep

Partnership

Volta Labs, a genomics applications company, and Watchmaker Genomics, a supplier of innovative products for molecular analysis, partner to leverage their technologies to power Volta’s short-read library prep kits.

Committment

Volta Labs and Watchmaker Genomics are jointly committed to making efficient, accessible, and cost-effective library prep a reality. With the launch of Volta’s Callisto™ Sample Prep System, Watchmaker Genomics will provide the reagents behind various VoltaPrep™ library prep kits.

Trey Foskett, CEO of Watchmaker Genomics

“Volta’s digital fluidics technology and their approach to building automated sample prep applications are impressive. Watchmaker has a passion for delivering superior data quality with simple and automatable workflows. Combining Volta’s cutting-edge technology with our innovative reagents delivers in both of these areas, and we look forward to a continued partnership.”

Udayan Umapathi, CEO at Volta Labs

“Watchmaker has set the bar high for enzyme engineering and library prep workflow development. We are energized to work with their talented team to address quality, cost, and scalability challenges that currently exist in sample prep. This collaboration is the first in a series of Volta applications that will be powered by Watchmaker chemistry.”

Callisto™ Sample Prep System

The Callisto™ Sample Prep System offers programmable, precise, and plastic-free liquid manipulation with pre-optimized applications to support short- and long-read sequencing workflows. With a growing menu of library prep kits powered by Watchmaker Genomics’ solutions, Volta will continue to expand the universe of pre-optimized applications available through Callisto and enable labs to maximize advancements in sequencing.

Sourceolta Labs

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”